WEST PHARMACEUTICAL SVSC INC's gross profit margin for the first quarter of its fiscal year 2015 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased, representing an increase to the bottom line. WEST PHARMACEUTICAL SVSC INC has average liquidity. Currently, the Quick Ratio is 1.34 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||335.9||346.8|
|Net Income ($mil)||32.9||27.1|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||207.1||230.0|
|Total Assets ($mil)||1596.0||1708.2|
|Total Debt ($mil)||330.7||404.9|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||39.21||36.97|
|Return on Assets||8.32||6.3|
|Return on Equity||14.12||11.52|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||71.9||70.5|
|Div / share||0.11||0.1|
|Book value / share||13.09||13.26|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||265000.0||321251.0|
BUY. WEST PHARMACEUTICAL SVSC INC's P/E ratio indicates a discount compared to an average of 35.91 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 20.55. To use another comparison, its price-to-book ratio of 4.50 indicates a significant premium versus the S&P 500 average of 2.84 and a significant discount versus the industry average of 6.40. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, WEST PHARMACEUTICAL SVSC INC proves to trade at a discount to investment alternatives within the industry.
|WST 32.18||Peers 35.91||WST 24.40||Peers 24.58|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
WST is trading at a discount to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
WST is trading at a valuation on par to its peers.
|WST 26.17||Peers 24.49||WST 11.29||Peers 1.00|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
WST is trading at a significant premium to its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
WST trades at a significant premium to its peers.
|WST 4.50||Peers 6.40||WST 21.19||Peers -1.09|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
WST is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
WST is expected to have an earnings growth rate that significantly exceeds its peers.
|WST 3.00||Peers 6.07||WST 2.52||Peers 10.85|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
WST is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
WST significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV